JP
Revvity Sites Globally
Select your location.
*e-commerce not available for this region.
Case Study
NIH NCATS case study: using accelerated screening research for SARS-CoV-2 drug repurposing candidates
Drug Repurposing can be an effective way to identify novel treatments for diseases, especially when time is of the essence.
Research scientists at National Center for Advancing Translational Sciences (NCATS), a part of the NIH, embarked on a drug repurposing strategy as the quickest route to generating data that would help the pharma industry drive towards an effective treatment for the COVID-19 virus.
Find out how in a matter of months the NCATS team was able to screen 3,384 molecular entities and narrow them down to a field of 25 quality "hits" capable of disrupting SARS-Cov-2 S1 protein:ACE2 receptor binding in this case study.
For research use only. Not for use in diagnostic procedures.
To view the full content please answer a few questions
Download Resource
NIH NCATS case study: using accelerated screening research for SARS-CoV-2 drug repurposing candidates